CN1836702A - Medicine for treating tumour and its preparing method - Google Patents
Medicine for treating tumour and its preparing method Download PDFInfo
- Publication number
- CN1836702A CN1836702A CN 200510041817 CN200510041817A CN1836702A CN 1836702 A CN1836702 A CN 1836702A CN 200510041817 CN200510041817 CN 200510041817 CN 200510041817 A CN200510041817 A CN 200510041817A CN 1836702 A CN1836702 A CN 1836702A
- Authority
- CN
- China
- Prior art keywords
- medicine
- tumor
- tremella
- cordyceps
- radix rehmanniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention discloses one new kind of tumor treating medicine and its preparation process. The tumor treating medicine is prepared into capsule with aweto, glossy ganoderma, prepared rhizome of rehmannia, tremella and fragrant mushroom and through a conventional process. The tumor treating medicine has the functions of inhibiting tumor, resisting radiation and resisting fatigue, and possesses unique curative effect on benign and malignant tumors and less toxic side effect.
Description
Technical field
What the present invention related generally to is the medicine of treatment tumor, is the preparation of feedstock production with Chinese medicine specifically, the invention still further relates to the preparation method of this medicine.
Background technology
Tumor is divided into benign tumor and malignant tumor two big classes usually by the characteristic of its growth with to the destructiveness of human body.The cellular morphology of carcinoid cellular morphology and normal structure is more approaching, well differentiated.Malignant tumor claims cancer again, is commonly called as malignant tumor, is a kind of grievous injury labour force, threatens the disease of people ' s health.The principal character of malignant tumor is a lump, and tangible levying hardly do not moved, and the speed of growth is very fast mostly, and boundary is not clear.The blood stasis that belongs to the traditional Chinese medical science is levied category.As untimely treatment the transitivity carcinoma can be arranged, thoroughly then not be easy to recurrence as treatment.Clinical confirmation, malignant tumor patient are in tangible blood level state of aggregation really, and the hypercoagulability of blood is general relevant with the weight of the state of an illness again.Along with constantly increasing the weight of of the state of an illness, cancerous cell is constantly grown, soaks into, is shifted, and body shows high blood coagulation trend gradually.Blood stasis is the main pathomechanism that tumor forms development, and appears at each pathology stage, thereby different times uses activating blood circulation to dissipate blood stasis side's medicine that tumor treatment is had the important clinical meaning.
Both at home and abroad to the treatment of primary disease, run into following thorny problem at present:
1, the operative treatment treatment can not be removed cancerous cell fully, may cause the incomplete or lopsided of health, has influence on some function of health.
2, the side reaction of chemicotherapy is big, has that gastricism, bone marrow depression, body are weak, an inflammatory reaction etc.
Though 3 also have the Chinese patent medicine of some treatment tumors, because formulation selection is improper or preparation technology's backwardness, make a lot of patients have to depend on the treatment of doctor trained in Western medicine.
Summary of the invention
The object of the present invention is to provide a kind of patient's tumor body that both can make to dwindle, suppress tumor cell proliferation, can improve the hypercoagulability of blood again, enhancing human body immunity alleviates or alleviates a kind of medicine and preparation method for the treatment of tumor of toxic and side effects of chemoradiotherapy.
A kind of medicine for the treatment of tumor of the present invention, it is to be made by the following weight proportion raw material:
Cordyceps 2-8 part, Ganoderma 10-50 part, Radix Rehmanniae Preparata 10-50 part, Tremella 10-50 part, Lentinus Edodes 10-50 part.
A kind of medicine for the treatment of tumor of the present invention, the preferred weight proportion scope of its raw material is:
Cordyceps 3-5 part, Ganoderma 25-30 part, Radix Rehmanniae Preparata 30-40 part, Tremella 30-40 part, Lentinus Edodes 30-40 part
A kind of medicine for the treatment of tumor of the present invention, the optimum weight ratio of its raw material is:
5 parts of Cordyceps, 30 parts of Ganodermas, 30 parts in Radix Rehmanniae Preparata, 30 parts in Tremella, 30 parts on Lentinus Edodes.
A kind of preparation method for the treatment of the medicine of tumor of the present invention is to carry out according to following steps:
After A, the Ganoderma with specified quantity, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes clean clean earth respectively, add 1200 parts of water logging bubbles 60 minutes, decoct after 2 hours, inclining, it is standby the squeezing decoction liquor, after the decocting that adds 10 times of amounts in raw material again boils 2 hours, merge twice decoction liquor standby;
B, the decoction liquor that steps A is made are evaporated to the thick paste shape, and its relative density is controlled at d=1.25 (50-55 ℃)-1.30 (50-55 ℃) in the concentrating under reduced pressure process, and vacuum drying is crushed to 16-18 order fine powder;
C, with the Cordyceps of specified quantity, in 35 ℃-38 ℃ oven dry down of low temperature, be crushed to 16-18 order fine powder, be used as medicine with former medicine;
D, with the above-mentioned Cordyceps that makes, Ganoderma, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes medicated powder mix homogeneously, with alcohol granulation, make granule at dry below 60 ℃, granulate;
E, with the made granule capsule of packing into No. 0, the 0.5g/ grain is equivalent to crude drug in whole 3.12g, again through pressing plate, vanning send irradiation sterilization promptly.
One Pharmacodynamic test of active extract of the present invention:
1, medicine matched group 0.15/kg of the present invention, 0.3/kg, three dosage groups of 0.6/kg, the cyclophosphamide positive controls is observed mice S180 sarcoma, mice H22 hepatocarcinoma, the influence of Mice Bearing Lewis Lung Cancer, see the following form:
Table 1A medicine of the present invention is to the inhibitory action of mice transplantability S180 sarcoma tumor bulk-growth
| Group | Number of animals | Body weight (g) | Heavy (g) X ± SD of tumor | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| Contrast | 10 | 18.5±1.17 | 26.9±1.44 | 1.20±0.45 | |
| Cyclophosphamide | 10 | 18.3±0.96 | 27.5±1.72 | 0.30±0.14 *** | 75％ |
| Test group 0.15g/kg | 10 | 18.5±1.41 | 27.4±2.01 | 1.10±0.47 | 8.3％ |
| Test group 0.30g/kg | 10 | 18.1±1.31 | 27.9±1.68 | 0.80±0.30 * | 33.3％ |
| Test group 0.6g/kg | 10 | 18.4±1.38 | 27.2±1.07 | 0.50±0.35 ** | 58.3％ |
Table 1B medicine of the present invention is to the inhibitory action of mice transplantability H22 hepatocarcinoma tumor bulk-growth
| Group | Number of animals | Body weight (g) | Heavy (g) X ± SD of tumor | Suppression ratio (%) | |
| Before the administration | After the administration | ||||
| Contrast | 10 | 20.4±1.44 | 27.1±2.03 | 2.20±0.42 | |
| Cyclophosphamide | 10 | 20.0±1.35 | 23.6±1.13 | 0.20±0.12 *** | 90.9％ |
| Test group 0.15g/kg | 10 | 20.0±1.16 | 24.2±1.22 | 1.50±0.79 * | 31.8％ |
| Test group 0.30g/kg | 10 | 19.6±0.82 | 26.1±2.47 | 1.20±0.43 *** | 45.5％ |
| Test group 0.6g/kg | 10 | 20.3±0.97 | 25.4±1.44 | 0.90±0.40 *** | 59.1％ |
Table 1C medicine of the present invention is to the inhibitory action of mice transplantability Lewis lung cancer tumor bulk-growth
| Group | Number of animals | Body weight (g) | Heavy (g) X ± SD of tumor | Suppression ratio (%) | |
| Before the administration | After the administration | ||||
| Contrast | 10 | 17.3±1.03 | 17.8±1.26 | 1.20±0.49 | |
| Cyclophosphamide | 10 | 17.4±0.87 | 18.1±0.76 | 0.10±0.04 | 91.7％ |
| Test group 0.15g/kg | 10 | 17.5±0.98 | 17.7±0.77 | 1.20±0.43 | 0 |
| Test group 0.30g/kg | 10 | 17.6±0.99 | 17.8±0.80 | 1.00±0.47 | 16.7％ |
| Test group 0.6g/kg | 10 | 17.2±0.84 | 17.3±0.79 | 0.60±0.14 *** | 50.0％ |
The result: medicine of the present invention is for the S180 sarcoma, mice H22 hepatocarcinoma, and Mice Bearing Lewis Lung Cancer all has the obvious suppression effect, and the high dose of three dosage groups (0.6g/kg) group suppression ratio reaches 62.3% respectively, 65.2%.61.5%.
2, medicine of the present invention and cyclophosphamide share the growth inhibiting potentiation of Mice Bearing Lewis Lung Cancer, see the following form:
Table 2 medicine of the present invention and cyclophosphamide share the growth inhibiting potentiation of Mice Bearing Lewis Lung Cancer
| Group | Dosage (mg/kg/day) | Number of animals | Body weight (g) | Tumor heavy (g) | Suppression ratio (%) | |
| Before the administration | After the administration | |||||
| Contrast | - | 10 | 19.2±1.0 | 19.4±1.8 | 3.322±0.47 | - |
| Cyclophosphamide | 20×1 | 10 | 19.3±0.8 | 21.5±2.6 | 2.376±0.50 | 28.46 a |
| Test group | 600×10 | 10 | 19.6±0.8 | 21.7±2.5 | 2.100±0.51 | 36.79 a |
| Test group ± cyclophosphamide | 150×10 | 10 | 19.5±1.0 | 20.0±1.8 | 2.434±0.36 | 26.72 |
| 300×10 | 10 | 19.7±1.1 | 19.3±2.6 | 1.764±0.29 | 46.90 b | |
| 600×10 | 10 | 19.8±1.0 | 19.7±1.8 | 1.532±0.37 | 54.39 c |
(a) p＜0.001 compares with matched group; (b) p＜0.01 compares (c) p＜0.001 with matched group, compare with matched group.
The result: medicine of the present invention (300,600mg/kg * 10) and cyclophosphamide (20mg/kg) share that growth has the obvious suppression potentiation to Mice Bearing Lewis Lung Cancer, and are certain dose-effect relationship
3, medicine of the present invention sees the following form to the immunization of tumor-bearing mice:
Table 3A medicine of the present invention is to the influence of mice reticuloendothelial system (RES) phagocytic function
| Group | Number of animals | Dosage (g/kg) | Phagocytic index (X ± D) |
| The blank group | 10 | 0.0185±0.0062 | |
| Test group | 10 | 0.25 | 0.0195±0.0055 |
| Test group | 10 | 0.5 | 0.0234±0.0101 |
| Test group | 10 | 1.0 | 0.0288±0.0104 |
| The ZHENQI FUZHENG JIAONANG group | 10 | 0.6 | 0.0347±0.015** |
Compare * P＜0.05, * * P＜0.01 with the blank group
The influence that table 3B medicine of the present invention generates the mice hemolytic antibody
| Group | Number of animals | Dosage (g/kg) | HC50(X±D) |
| The blank group | 10 | 13.5±3.22 | |
| Test group | 10 | 0.25 | 14.84±2.83 |
| Test group | 10 | 0.5 | 15.72±3.42 |
| Test group | 10 | 1.0 | 21.75±4.38** |
| The ZHENQI FUZHENG JIAONANG group | 10 | 0.6 | 32.11±7.36** |
Compare * P＜0.05, * * P＜0.01 with the blank group
Table 3C medicine of the present invention is to the influence of mice peripheral blood T cells percentage ratio
| Group | Number of animals | Dosage (g/kg) | Peripheral blood T cells percentage ratio (X ± D) |
| The blank group | 10 | 39.41±7.46 | |
| Test group | 10 | 0.25 | 43.4±6.05 |
| Test group | 10 | 0.5 | 41.12±6.31 |
| Test group | 10 | 1.0 | 44.00±7.94 |
| The ZHENQI FUZHENG JIAONANG group | 10 | 0.6 | 46.61±5.01* |
Compare * P＜0.05, * * P＜0.01 with the blank group
The result: 1 pair of mice reticuloendothelial system phagocytic function has obvious potentiation; 2 pairs of humoral immune functions have potentiation; 3 pair cell immunologic functions, medicine of the present invention have the trend that improves T lymphocyte percentage ratio in the mice peripheral blood.
4, medicine of the present invention sees the following form to the inhibitory action of nude mouse xenotransplantation tumor people small cell carcinoma growth:
Table 4 medicine of the present invention is to the effect of transplanted tumor in nude mice people small cell carcinoma growth inhibited
| Group | Number of animals | Body weight (g) | Heavy (g) X ± SD of tumor | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| Negative control | 6 | 21.5±1.05 | 24.5±2.43 | 2.45±0.786 | |
| Cyclophosphamide 100mg/kg | 6 | 21.0±1.26 | 20.8±1.72 | 0.27±0.186 ** | 89.0 |
| Test group 0.15g/kg | 6 | 20.1±1.17 | 24.0±1.55 | 1.55±1.13 | 36.7 |
| Test group 0.30g/kg | 6 | 21.5±1.05 | 22.4±3.78 | 1.38±0.657 * | 43.7 |
| Test group 0.6g/kg | 6 | 20.3±1.63 | 22.5±3.73 | 1.08±0.417 * | 55.9 |
*：P＜0.05 **P＜0.01
The result: medicine of the present invention is planted the growth of tumor small cell lung cancer to people's cancer nude mouse xenogenesis and is had the obvious suppression effect, and shows the doses effect relation.
5, to acute toxicity test in mice and chronic toxicity test respectively with 50 times and 83 times of people's clinical dosage, hyperpraxia does not appear, do not have special secretions, do not find that to liver the infringement of internal organs such as kidney and toxic and side effects see the following form:
Table 5A drug oral administration of the present invention influence to the male rat hematological indices in three months
| Group | Lymph % | Neutral % | Have a liking for sour % | Monokaryon % | Net is knitted % | WBC (×10 9/L) | RBC (×10 12/L) | HGB (g/L) | PLT (× 10 9/L) |
| Matched group | 83.5±3.0 | 15.3±3.6 | 1.0±0.8 | 0.3±0.5 | 2.3±0.7 | 44.2±42.6 | 5.77±1.80 | 145± 2 | 522±7 8 |
| Test group 1g/kg | 84.0±2.9 | 14.5±1.7 | 1.3±1.0 | 0.3±0.5 | 2.4±0.4 | 55.4±53.1 | 5.52±1.37 | 147± 10 | 605±1 53 |
| Test group 3g/kg | 88.8±1.0 * | 10.5±1.3 * | 0.3±0.5 | 0.5±0.6 | 1.1±0.8 | 39.6±32.0 | 5.36±0.52 | 144± 7 | 578±8 9 |
| Test group 5g/kg | 88.8±2.5 * | 10.3±2.4 | 0.5±0.6 | 0.5±0.6 | 2.3±0.4 | 18.7±11.0 | 4.23±0.36 | 121± 8 *** | 572±7 9 |
Compare * P＜0.05, * * * P＜0.001 with matched group
Table 5B drug oral administration of the present invention influence to the female rats hematological indices in three months
| Group | Lymph % | Neutral % | Have a liking for sour % | Monokaryon % | Net is knitted % | WBC (×10 9/L) | RBC (×10 12/L) | HGB (g/L) | PLT (× 10 9/L) |
| Matched group | 84.0±1.8 | 14.8±2.8 | 1.0±0.8 | 0.3±0.5 | 2.1±0.3 | 23.3±22.9 | 5.54±0.67 | 141±10 | 548±4 5 |
| Test group 1g/kg | 87.8±3.0 | 11.5±2.6 | 0.5±0.6 | 0.3±0.5 | 2.6±0.5 | 24.2±23.4 | 5.34±0.69 | 138±7 | 630±1 22 |
| Test group 3g/kg | 86.5±3.4 | 12.3±3.3 | 1.0±0.0 | 0.3±0.5 | 2.0±0.4 | 9.4±0.7 | 5.41±0.37 | 133±2 | 505±7 9 |
| Test group 5g/kg | 81.0±1.4 * | 17.8±2.2 | 0.8±1.0 | 0.5±0.6 | 2.3±0.4 | 15.4±8.5 | 4.56±0.43 * | 130±11 | 560±7 7 |
Compare with matched group, * P＜0.05,
The oral medicine of the present invention of male rat except that the normal matched group of reticulocyte and platelet slightly raises (P＜0.05), did not have influence to other hematological indices after three months.Convalescent period middle and high dosage group lymph and neutrophilic granulocyte occur outside the fluctuation, also see heavy dose of group HB descend (P＜0.001).
Jenny sees that also heavy dose of group PLT raises except that small dose group lymph and neutrophilic granulocyte appearance variation.Convalescent period, other indexs were compared there was no significant difference with matched group except that heavy dose group lymphocyte and erythrocyte appearance fluctuation
Two, clinical data of the present invention
1, case history is selected: among 200 patients of this case history, and male 136 examples, women 64 examples.Oldest 83 years old, minimum 29 years old.Pulmonary carcinoma 71 examples wherein are comprising scale cancer 49 examples, adenocarcinoma 15 examples, small cell carcinoma 7 examples; The esophageal carcinoma 29 examples, hepatocarcinoma 15 examples, gastric cancer 33 examples, bladder cancer 25 examples, cervical cancer 18 examples, the cerebral tumor 9 examples.Above case history is all made a definite diagnosis through provincial hospital cell sight glass or inspections such as pathological section and video.
2, instructions of taking:
The treatment group: general tumor patient is taken each two of the normal dose of medicine of the present invention, every day four times.The patient with severe symptoms can add the 1-2 grain at every turn.Dysphagia person can be with medicated powder in the capsule with pure Mel furnishing pasty state, containing.Took continuously three months.
Matched group: give cyclophosphamide, the Therapeutic Method and the course of treatment are with the treatment group.Two groups of treatments are three months.
3, diagnostic criteria: clinical cure: patient's mental status is good, and appetite is normal, the oncothlipsis transference cure, and the tumor body narrows down to more than 50%, no longer increases or complete obiteration.
Produce effects: patient's pain relief, spirit takes a turn for the better, and appetite amelioration, tumor body have obviously and dwindle.
Effectively: pain alleviates to some extent, and the mental status is good, and appetite is normal.The tumor body dwindles not obvious.
Invalid: patient's pain does not have and alleviates, and basal status is poor, and the tumor body does not dwindle trend or death.
4, therapeutic outcome:
Clinical cure 7 examples account for 4% in the treatment group, and produce effects 85 examples account for 42%, and effective 95 examples account for 47%, and invalid 13 examples account for 7%.Total effective rate 93%.Clinical cure example 3 examples account for 6% in the matched group, and produce effects 21 examples account for 42%, and effective 21 examples account for 42%, and invalid 5 examples account for 10%, and total effective rate is that 90%, two group of total effective rate is variant, sees the following form:
| Group | The example number | Comprehensive therapeutic effect is judged % | Total effective rate % | |||
| Clinical cure | Produce effects | Effectively | Invalid | |||
| The treatment group | 200 | 4 | 42 | 47 | 7 | 93％ |
| Matched group | 50 | 6 | 42 | 42 | 10 | 90％ |
Two groups of curative effects credit are by statistics analysed P＜0.05
Three, result of the test of the present invention shows:
1, to select natural Tibetan medicine and Chinese medicine for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation.Utilize the comprehensive function treatment tumor of the Chinese medicine of respectively distinguishing the flavor of, little to the human body side effect.
2, the present invention need not decoct, no bitterness sense, and taking convenience meets the national health law regulation.
3, the present invention can suppress the advolution of tumor cell, promotes the death of tumor cell, has tangible antimutagenic effect.
4, the present invention can use separately, also can cooperate put, chemotherapy uses, and can play the curative effect that increases chemicotherapy, alleviates the toxic and side effects of chemicotherapy.
Four, medicine of the present invention is applicable to following crowd:
1, various malignant tumor patients of early, middle and late phase;
2, put, the malignant tumor patient of chemotherapy;
3, perioperatively is put, convalescent patient after the chemotherapy;
4, because of a variety of causes can not undergo surgery and put, the patient of chemotherapy;
5, various carcinoid patients.
Instructions of taking and consumption:
Each two of the general normal dose of tumor patient, every day four times.The patient with severe symptoms can add the 1-2 grain at every turn.Dysphagia person can be with the medicated powder in the capsule with pure Mel furnishing pasty state, containing.
The specific embodiment
Embodiment 1
A kind of preparation method for the treatment of the medicine of tumor of the present invention is to carry out according to following steps: A, with Ganoderma 30g, Radix Rehmanniae Preparata 30g, Tremella 30g, Lentinus Edodes 30g, respectively clean clean earth after, adding 1200 ml waters earlier soaked 60 minutes, decocted 2 hours, during decoction after water boiling, changing little fire into decocts, the temperature that little fire decocts is controlled at 90---and 110 ℃, inclining, it is standby the squeezing decoction liquor.The decocting that adds 1200 milliliters in raw material again boiled 2 hours, decocted after the water boiling, changed little fire into and decocted, and the temperature that little fire decocts is controlled at 90---110 ℃, merge twice decoction liquor standby then.B, the decoction liquor that steps A is made are evaporated to the thick paste shape, and its relative density is controlled at d=1.25 (50-55 ℃) in the concentrating under reduced pressure process, and vacuum drying is crushed to 16 purpose fine powders.C, with Cordyceps 5g, in the oven dry down of 35 ℃ of low temperature, be crushed to 16 order fine powders, be used as medicine with former medicine.D, with above-mentioned Cordyceps, Ganoderma, Radix Rehmanniae Preparata, Tremella, the Lentinus Edodes medicated powder mix homogeneously of making, with 80% alcohol granulation, make granule at dry below 60 ℃, granulate.E, with the made granule capsule of packing into No. 0, the 0.5g/ grain is equivalent to crude drug in whole 3.12g, again through pressing plate, vanning send irradiation sterilization promptly.
Embodiment 2
A kind of preparation method for the treatment of the medicine of tumor of the present invention is to carry out according to following steps: A, with Ganoderma 30g, Radix Rehmanniae Preparata 30g, Tremella 30g, Lentinus Edodes 30g, respectively clean clean earth after, adding 1200 ml waters earlier soaked 60 minutes, decocted 2 hours, during decoction after water boiling, changing little fire into decocts, the temperature that little fire decocts is controlled at 100 ℃, and inclining, it is standby the squeezing decoction liquor.The decocting that adds 1200 milliliters in raw material again boiled 2 hours, decocted after the water boiling, changed little fire into and decocted, and the temperature that little fire decocts is controlled at 100 ℃, merges twice decoction liquor standby then.B, the decoction liquor that steps A is made are evaporated to the thick paste shape, and its relative density is controlled at d=1.25 (50-55 ℃) in the concentrating under reduced pressure process, and vacuum drying is crushed to 16 purpose fine powders.C, with Cordyceps 5g, in the oven dry down of 35 ℃ of low temperature, be crushed to 16 order fine powders, be used as medicine with former medicine.D, with above-mentioned Cordyceps, Ganoderma, Radix Rehmanniae Preparata, Tremella, the Lentinus Edodes medicated powder mix homogeneously of making, add excipient and make tablet, every 0.5g is equivalent to crude drug in whole 2.5g, again through pressing plate, vanning send irradiation sterilization promptly.
Claims (5)
1. medicine for the treatment of tumor is characterized in that it is to be made by the following weight proportion raw material:
Cordyceps 2-8 part, Ganoderma 10-50 part, Radix Rehmanniae Preparata 10-50 part,
Tremella 10-50 part, Lentinus Edodes 10-50 part.
2. a kind of medicine for the treatment of tumor according to claim 1, it is characterized in that it be by the following weight proportioning raw material make:
Cordyceps 3-5 part, Ganoderma 25-30 part, Radix Rehmanniae Preparata 30-40 part,
Tremella 30-40 part, Lentinus Edodes 30-40 part.
3. a kind of medicine for the treatment of tumor according to claim 1, it is characterized in that it be by the following weight proportioning raw material make:
5 parts of Cordyceps, 30 parts of Ganodermas, 30 parts in Radix Rehmanniae Preparata, 30 parts in Tremella, 30 parts on Lentinus Edodes.
4. a kind of preparation method for the treatment of the medicine of tumor as claimed in claim 1 is characterized in that it is to be undertaken by following steps:
After A, the Ganoderma with specified quantity, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes clean clean earth respectively, add 1200 parts of water logging bubbles 60 minutes, decoct after 2 hours, inclining, it is standby the squeezing decoction liquor, after the decocting that adds 10 times of amounts in raw material again boils 2 hours, merge twice decoction liquor standby;
B, the decoction liquor that steps A is made are evaporated to the thick paste shape, and its relative density is controlled at d=1.25 (50-55 ℃)-1.30 (50-55 ℃) in the concentrating under reduced pressure process, and vacuum drying is crushed to 16-18 purpose fine powder;
C, with the Cordyceps of specified quantity, in 35 ℃-38 ℃ oven dry down of low temperature, be crushed to 16-18 purpose fine powder, be used as medicine with former medicine;
D, with the above-mentioned Cordyceps that makes, Ganoderma, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes medicated powder mix homogeneously, with alcohol granulation, make granule at dry below 60 ℃, granulate;
E, with the made granule capsule of packing into No. 0, again through pressing plate, vanning send irradiation sterilization promptly.
5. a kind of preparation method for the treatment of the medicine of tumor as claimed in claim 1 is characterized in that it is to be undertaken by following steps:
After A, the Ganoderma with specified quantity, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes clean clean earth respectively, add 1200 parts of water logging bubbles 60 minutes, decoct after 2 hours, inclining, it is standby the squeezing decoction liquor, after the decocting that adds 10 times of amounts in raw material again boils 2 hours, merge twice decoction liquor standby;
B, the decoction liquor that steps A is made are evaporated to the thick paste shape, and its relative density is controlled at d=1.25 (50-55 ℃)-1.30 (50-55 ℃) in the concentrating under reduced pressure process, and vacuum drying is crushed to 16-18 purpose fine powder;
C, with the Cordyceps of specified quantity, in 35 ℃-38 ℃ oven dry down of low temperature, be crushed to 16-18 purpose fine powder, be used as medicine with former medicine;
D, with the above-mentioned Cordyceps that makes, Ganoderma, Radix Rehmanniae Preparata, Tremella, Lentinus Edodes medicated powder mix homogeneously, add excipient and make tablet, again through pressing plate, vanning send irradiation sterilization promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041817 CN1836702A (en) | 2005-03-21 | 2005-03-21 | Medicine for treating tumour and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041817 CN1836702A (en) | 2005-03-21 | 2005-03-21 | Medicine for treating tumour and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1836702A true CN1836702A (en) | 2006-09-27 |
Family
ID=37014296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041817 Pending CN1836702A (en) | 2005-03-21 | 2005-03-21 | Medicine for treating tumour and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1836702A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319379A (en) * | 2009-03-05 | 2012-01-18 | 郝基荣 | Formula for treating and preventing cancerous tumors and preparation and production process of Chinese caterpillar fungus tumor rehabilitation oral liquid |
| CN104069253A (en) * | 2014-06-18 | 2014-10-01 | 石家庄蒙誉生物科技有限公司 | Traditional Chinese medicine for treating tumors |
| CN106668841A (en) * | 2015-11-05 | 2017-05-17 | 吴长海 | Anti-tumor yak ossein protein peptide composition and preparation method thereof |
-
2005
- 2005-03-21 CN CN 200510041817 patent/CN1836702A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319379A (en) * | 2009-03-05 | 2012-01-18 | 郝基荣 | Formula for treating and preventing cancerous tumors and preparation and production process of Chinese caterpillar fungus tumor rehabilitation oral liquid |
| CN104069253A (en) * | 2014-06-18 | 2014-10-01 | 石家庄蒙誉生物科技有限公司 | Traditional Chinese medicine for treating tumors |
| CN106668841A (en) * | 2015-11-05 | 2017-05-17 | 吴长海 | Anti-tumor yak ossein protein peptide composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1706473A (en) | Anticancer taxad Chinese medicine prepn | |
| CN101125178A (en) | Traditional Chinese medicine for treating tumor | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1836702A (en) | Medicine for treating tumour and its preparing method | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN1836683B (en) | Medicine for treating tumour and its preparing method | |
| CN1225258C (en) | Chinese medicine compound preparation for curing pancreatic cancer | |
| CN1513497A (en) | Immunity regulation medicine composition, and its prepn. method | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1054541C (en) | Traditional Chinese medicine for treating mastosis | |
| CN1276764C (en) | Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method | |
| CN1483468A (en) | Huaaidan pellet medicine for treating cancer and preparation method thereof | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1836707A (en) | Medicine for treating tumour and its preparing method | |
| CN1628826A (en) | Medicine for treating cancer | |
| CN104056207B (en) | Traditional Chinese medicine combination for treating stomach cancer and preparation method for same | |
| CN1185006C (en) | Chinese medicine composition for accessory treatment of primary liver cancer and preparing method thereof | |
| CN1422641A (en) | Medicine for treating cancerous thoracoascites and preparation method | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN107362296B (en) | Medicine for treating benign tumor of skin and preparation method thereof | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1679908A (en) | Chinese medicine for treating tumor and preparation thereof | |
| CN1513539A (en) | Preparation technology of supplementing kind capsule | |
| CN1861100A (en) | External use oil agent for treating proliferation of mammary gland and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20060927 |